Estimation of clinical benefit and economic burden for using a commercial 70-gene signature test for Brazilian breast cancer patients in the public health system (2021)
- Authors:
- USP affiliated authors: ANDRADE, JURANDYR MOREIRA DE - FMRP ; TIEZZI, DANIEL GUIMARÃES - FMRP ; BUZATTO, ISABELA PANZERI CARLOTTI - FMRP ; RODRIGUES, TAMARA CRISTINA GOMES FERRAZ - FMRP ; BORBA, JÉSSICA MARIA CAMARGO - FMRP
- Unidade: FMRP
- DOI: 10.1158/1538-7445.SABCS20-PS9-27
- Subjects: NEOPLASIAS MAMÁRIAS; NEOPLASIAS MAMÁRIAS; MENOPAUSA; SISTEMA ÚNICO DE SAÚDE
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2021
- Source:
- Título: Cancer Research
- ISSN: 0008-5472
- Volume/Número/Paginação/Ano: v. 81, n. 4, suppl., res. PS9-27, 2021
- Conference titles: San Antonio Breast Cancer Virtual Symposium
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
PIMENTEL, Franklin Fernandes et al. Estimation of clinical benefit and economic burden for using a commercial 70-gene signature test for Brazilian breast cancer patients in the public health system. Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. Disponível em: https://doi.org/10.1158/1538-7445.SABCS20-PS9-27. Acesso em: 29 dez. 2025. , 2021 -
APA
Pimentel, F. F., Buzatto, I. P. C., Rodrigues, T. C. G. F., Borba, J. M. C., Peruchi, K. P. I., Andrade, J. M. de, & Tiezzi, D. G. (2021). Estimation of clinical benefit and economic burden for using a commercial 70-gene signature test for Brazilian breast cancer patients in the public health system. Cancer Research. Philadelphia: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. doi:10.1158/1538-7445.SABCS20-PS9-27 -
NLM
Pimentel FF, Buzatto IPC, Rodrigues TCGF, Borba JMC, Peruchi KPI, Andrade JM de, Tiezzi DG. Estimation of clinical benefit and economic burden for using a commercial 70-gene signature test for Brazilian breast cancer patients in the public health system [Internet]. Cancer Research. 2021 ; 81( 4):[citado 2025 dez. 29 ] Available from: https://doi.org/10.1158/1538-7445.SABCS20-PS9-27 -
Vancouver
Pimentel FF, Buzatto IPC, Rodrigues TCGF, Borba JMC, Peruchi KPI, Andrade JM de, Tiezzi DG. Estimation of clinical benefit and economic burden for using a commercial 70-gene signature test for Brazilian breast cancer patients in the public health system [Internet]. Cancer Research. 2021 ; 81( 4):[citado 2025 dez. 29 ] Available from: https://doi.org/10.1158/1538-7445.SABCS20-PS9-27 - Axillary ultrasound and fine-needle aspiration cytology to predict clinically relevant nodal burden in breast cancer patients
- Evaluation of factors related to efficacy and safety of neo/adjuvant chemotherapy for breast cancer as a brief estimate of the impact of COVID-19 pandemic
- Volume of breast tissue excised during breast-conserving surgery in patients undergoing preoperative systemic therapy
- Expression of hypoxia-inducible factor 1-'alfa' and vascular endothelial growth factor-C in locally advanced breast cancer patients
- Mouse renal 4T1 cell engraftment as a model to study the influence of hypoxia in breast cancer progression
- Expression of aldehyde dehydrogenase after neoadjuvant chemotherapy is associated with expression of hypoxia-inducible factors 1 and 2 alpha and predicts prognosis in locally advanced breast cancer
- Recurrence and survival after neoadjuvant chemotherapy for locally advanced cervical cancer is dependent on the pathological response
- Development of new formulations of biologics: expectations, immunogenicity, and safety for subcutaneous trastuzumab
- Fatores de predição de resposta ao tratamento neoadjuvante com trastuzumabe associado à quimioterapia em pacientes com câncer de mama HER2 positivo
- Avaliação termográfica das pacientes submetidas a quimioterapia neoadjuvante
Informações sobre o DOI: 10.1158/1538-7445.SABCS20-PS9-27 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 |
003204044.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
